Abstract
AbstractPatients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T‐cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high‐dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T‐cell therapy, BsAbs, or long‐term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high‐risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
